CPI Logo-Color.png
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
October 10, 2018 16:30 ET | Constellation Pharmaceuticals , Inc.
– Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...
CPI Logo-Color.png
Constellation Pharmaceuticals Congratulates Dr. David Allis and Dr. Michael Grunstein, Winners of the 2018 Lasker Award
September 12, 2018 09:00 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST) today congratulated Dr. C. David Allis and Dr. Michael Grunstein, the co-recipients of the...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Appointments to Board of Directors
September 04, 2018 06:30 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and...
CPI Logo-Color.png
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial Results
August 14, 2018 16:15 ET | Constellation Pharmaceuticals , Inc.
Company raises an aggregate of $160 million in crossover financing in April and initial public offering (IPO) in JulyCompany progressing its pipeline, including clinical programs CPI-1205 and CPI-0610...
Constellation Pharmaceuticals Announces Pricing of Initial Public Offering
July 18, 2018 19:56 ET | Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”)(Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...